Follow Novavax to never miss an important update.
Novavax reported a loss of 19 cents per share, which was better than the 35-cent loss analysts had predicted. Revenue reached 68 million dollars for the quarter, also beating expectations. The company raised its full-year revenue forecast to about 400 million dollars, a significant jump from its previous outlook.
This growth is largely tied to its partnership with Sanofi, a global pharmaceutical giant. Novavax earned a 125 million dollar payment in October after Sanofi started a late-stage trial for a combined flu and COVID-19 vaccine in Europe. By letting Sanofi handle the expensive clinical trials and manufacturing, Novavax is successfully shifting to a leaner model that relies on royalties and milestone payments rather than selling vaccines itself.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Shah Capital, an investment firm that had been publicly pushing Novavax to change its strategy and board, has decided to step back from its activist role. Activist investors typically buy large stakes to pressure management into making changes they believe will raise the stock price.
This move suggests that Shah Capital is satisfied with the company's recent pivot. Novavax has lately moved away from manufacturing its own vaccines and toward licensing its technology to larger partners like Sanofi. For long-term owners, this reduces the risk of public infighting and indicates that major shareholders are now aligned with the current plan.
Source: Reuters
Management has built a reliable habit of clearing the bars they set for themselves. Seven beats in the last eight quarters suggest they have a firm handle on their costs and partnership timelines.
| Expectation | |
|---|---|
| EPS | $-0.35 |
| Revenue | $50M |